Volume 29, Issue 4 pp. 620-628
ORIGINAL ARTICLE

Limited Utility of Serum Hepcidin as a Marker for Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients: An Analysis From the INFINITY Cohort

Tomomi Matsuoka

Tomomi Matsuoka

Division of Nephrology, Hypertension, and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for more papers by this author
Hyoe Tomita

Hyoe Tomita

Yujin Clinic, Tokyo, Japan

Yujin Oizumigakuen Clinic, Tokyo, Japan

Search for more papers by this author
Tetsuo Tagami

Tetsuo Tagami

Yujin Oizumigakuen Clinic, Tokyo, Japan

Search for more papers by this author
Noriaki Maruyama

Noriaki Maruyama

Akabane Central General Hospital Dialysis Clinic, Tokyo, Japan

Search for more papers by this author
Makoto Yasuo

Makoto Yasuo

Ishin Clinic, Tokyo, Japan

Search for more papers by this author
Chinami Nagura

Chinami Nagura

Shiki Ekimae Clinic, Saitama, Japan

Asakadai Dialysis Clinic, Saitama, Japan

Search for more papers by this author
Akiko Tsunemi

Akiko Tsunemi

Division of Nephrology, Hypertension, and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for more papers by this author
Yoshihiro Nakamura

Yoshihiro Nakamura

Division of Nephrology, Hypertension, and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for more papers by this author
Takashi Maruyama

Takashi Maruyama

Division of Nephrology, Hypertension, and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Search for more papers by this author
Masanori Abe

Corresponding Author

Masanori Abe

Division of Nephrology, Hypertension, and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Correspondence:

Masanori Abe ([email protected])

Hiroki Kobayashi ([email protected])

Search for more papers by this author
Hiroki Kobayashi

Corresponding Author

Hiroki Kobayashi

Division of Nephrology, Hypertension, and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan

Correspondence:

Masanori Abe ([email protected])

Hiroki Kobayashi ([email protected])

Search for more papers by this author
First published: 15 May 2025

Funding: The authors received no specific funding for this work.

ABSTRACT

Background

Although erythropoiesis-stimulating agents (ESAs) have improved anemia management, some patients on maintenance hemodialysis (HD) exhibit hyporesponsiveness. Hepcidin, a key regulator of iron homeostasis, may play a role in this process. However, its potential as a marker for ESA hyporesponsiveness remains unclear due to conflicting findings of previous studies. This study aimed to evaluate serum hepcidin-25 as a marker for ESA hyporesponsiveness and identify factors influencing hepcidin levels in HD patients.

Methods

This prospective observational study included 478 HD patients receiving ESA from the INFINITY cohort. Blood samples were collected before and after ESA administration to measure serum hepcidin-25. ESA hyporesponsiveness was defined by an erythropoietin resistance index (ERI) of 15 or higher. Logistic regression and linear regression analyses were used to identify factors associated with ESA hyporesponsiveness and hepcidin levels.

Results

Among patients receiving ESAs, 15% were classified as hyporesponsive. In the darbepoetin alpha group, hyporesponsive patients had lower hepcidin-25 levels; however, this association was not retained in multivariable analysis. No difference in hepcidin was observed in the recombinant human erythropoietin (EPO) group. Higher C-reactive protein (CRP), ferritin, transferrin saturation (TSAT), albumin, and glycoalbumin were linked to increased hepcidin, while being male and higher ESA dosage were associated with lower hepcidin levels.

Conclusions

Hepcidin-25 levels were lower in ESA hyporesponsive patients; however, the association was not significant in multivariable analysis. Thus, routine measurement of hepcidin may not be necessary for diagnosing ESA hyporesponsiveness. The novel association between hepcidin and glycoalbumin suggests an interaction between iron regulation and glucose metabolism, warranting further study.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.